Attitudes, beliefs toward end-of-life care differ between hematologic, solid tumor specialists
the ONA take:
Researchers at the University of Texas MD Anderson Cancer Center conducted a survey to compare the attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
They randomly surveyed 120 hematologists and 120 solid tumor oncologists at the institution; 182 clinicians (76%) responded.
The survey questions examined the participants’ attitudes toward various aspects of end-of-life care, including use of palliative systemic therapy.
The researchers found significant differences in attitudes and beliefs toward end-of-life care. Hematologic specialty and comfort level with prescribing treatment to patients with Eastern Cooperative Oncology Group performance status 4 and an expected survival of 1 month were associated with the decision to treat in the last month of life.
Survey compares attitudes and beliefs toward palliative care among hematologic versus solid tumor specialists.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|